Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
AssigneeHealth Maintenance Programs, Inc.
InventorHarry B. Demopoulos
Life of this patent
Estimating the term…
Abstract
The present invention relates to formulations and methods for preventing and treating restenosis following angioplasty. This is accomplished by the regimented administration of a composition which includes selected antioxidants.
Claims18
A pharmaceutically active antioxidant containing composition consisting essentially of a formulation including L-ascorbic acid, reduced form, in an amount of between about 6,500 and about 10,000 mg;
- L-glutathione, reduced form, in an amount of between about 325 and about 500 mg;
- D,L-alpha tocopheryl acetate in an amount of between about 600 and about 1,000 IU;
- and beta carotene in an amount of between about 90 and about 150 mg;
- said composition capable of being administered in four substantially equal dosages throughout a single 24 hour period and said composition being effective in the prevention and treatment of restenosis in mammalian organisms in need thereof.
A pharmaceutically active antioxidant containing composition consisting essentially of a formulation including L-ascorbic acid, reduced form, in an amount of between about 6,500 and about 10,000 mg;
- calcium carbonate in an amount of between about 1,900 and about 3,000 mg, calcium D-pantothenate in an amount of between about 800 and about 1,200 mg;
- L-glutathione, reduced form, in an amount of between about 325 and about 500 mg;
- D,L-alpha tocopheryl acetate in an amount of between about 600 and about 1,000 IU;
- thiamine hydrochloride in an amount of between about 250 and about 400 mg;
- pyridoxine hydrochloride in an amount of between about 135 and about 200 mg;
- beta carotene in an amount of between about 90 and about 150 mg;
- niacinamide in an amount of between about 100 and about 150 mg;
- niacin in an amount of between about 35 and about 50 mg;
- riboflavin in an amount of between about 25 mg and about 40 mg;
- cyanocobalamin in an amount of between about 1,000 and about 1,500 micrograms, and cholecalciferol in an amount of between about 400 and about 650 IU;
- said composition capable of being administered in four substantially equal dosages throughout a single 24 hour period and said composition being effective in the prevention and treatment of restenosis in mammalian organisms in need thereof.
A method of preventing and treating restenosis in mammalian organisms, said method comprising the step of administering, in each 24 hour period, a formulation including the compounds L-ascorbic acid in reduced form, L-glutathione in reduced form, D,L-alpha tocopheryl acetate, and beta carotene, each of said compounds of said formulation being present in an amount effective to treat and to prevent the formation of restenosis, to a mammalian organism in need of such treatment.
A method of preventing and treating restenosis in a mammalian organism, said method comprising the step of administering, in each 24 hour period, a formulation which includes L-ascorbic acid in reduced form, calcium carbonate, calcium D-pantothenate, L-glutathione in reduced form, D,L-alpha tocopheryl acetate, thiamine hydrochloride, pyridoxine hydrochloride, beta carotene, niacinamide, niacin, riboflavin, cyanocobalamin, cholecalciferol, each of the compounds of said formulation being present in an amount effective to treat and to prevent the formation of restenosis, to a mammalian organism in need of such treatment.
Dependencies are inferred from the claim text.